Regulatory press releases

Nanologicas delårsrapport jan-mar 2022

29 April, 2022

PERIODEN I KORTHET FINANSIELL SAMMANFATTNING Nettoomsättningen för första kvartalet uppgick till 270 TSEK (5 622) Rörelseresultatet uppgick till -15 592 TSEK (-6 768) Resultatet efter skatt uppgick till -15 915 TSEK (-7 845) Resultat per aktie före och efter utspädning var -0,57 SEK (-0,28) Likvida medel uppgick per den 31 mars 2022 till 3 969 TSEK (57 069) VÄSENTLIGA HÄNDELSER UNDER FÖRSTA KVARTALET I januari tecknas en lånefacilitet om upp till 50 MSEK med bolagets huvudägare

Trading in Nanologica’s shares on Nasdaq Stockholm commences today

29 March, 2022

Nanologica AB (publ) announces that the company’s shares are admitted for trading on Nasdaq Stockholm’s main market today. “Nanologica is about to launch a world-class product within chromatography that can cut costs for insulin manufacturers, which may enable treatment for more diabetes patients. At the same time, we are progressing our unique platform for local delivery of drugs to the lung through internal development, with the goal of giving patients with severe lung diseases access

Nanologica Publishes Prospectus in Connection with the Listing on Nasdaq Stockholm

21 March, 2022

On 11 March 2022, Nanologica AB (publ) announced that Nasdaq Stockholm’s Listing Committee had approved that the company’s shares are admitted to trading on Nasdaq Stockholm’s main market, conditioned upon customary conditions being fulfilled. The prospectus prepared in connection with the listing has today been approved and registered by the Swedish Financial Supervisory Authority and is now available on Nanologica’s website www.nanologica.com and will be made available on the Swedish Financial Supervisory Authority’s website www.fi.se.

Nanologica has been Approved for Listing on Nasdaq Stockholm

11 March, 2022

Nanologica AB (publ) announces that Nasdaq Stockholm’s Listing Committee has approved the company’s application for admission to trading of the company’s shares on Nasdaq Stockholm’s main market. The approval is conditioned upon customary conditions being fulfilled, including the approval and registration of a prospectus by the Swedish Financial Supervisory Authority. The first day of trading on Nasdaq Stockholm’s main market is scheduled for Tuesday 29 March 2022 and the last day of trading on Spotlight

Nanologica Publishes Annual Report for 2021

9 March, 2022

Nanologica’s annual report for the financial year 2021 has been published and is now available on the company’s website. The annual report can be downloaded from the company’s website www.nanologica.com (Investor Relations/Finansiella rapporter) and is also attached to the press release. An English translation of the annual report is expected to be available on the company’s website in mid-March. For further information, please contact: Johanna Johansson, Director IR, Communications and Marketing Ph: +46

Nanologica’s Year-End Report 2021

8 February, 2022

FINANCIAL SUMMARY Net sales for the fourth quarter amounted to TSEK 676 (6,071) and for the full year to TSEK 12,914 (16,135) The operating result for the fourth quarter amounted to TSEK -14,108 (-3,648) and for the full year to TSEK -40,689 (-19,571) Result after tax for the fourth quarter amounted to TSEK -15,222 (-5,427) and for the full year to TSEK -44,829 (-22,199) Earnings per share before and after dilution were SEK -0,54 (-0,20)

About us

Nanologica is a Swedish life science tools company that develops, manufactures, and sells advanced consumables to pharmaceutical manufacturers. Nanologica’s products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to effective purification and a long lifetime for the products, they can increase productivity and reduce costs for pharmaceutical manufacturers. Nanologica operates in a global niche market that is growing as a result of increased demand for drugs for the treatment of diabetes and obesity. The company’s mission is to increase access to cost-effective drugs through its purification products and thereby contribute to more patients around the world having access to life-saving treatments. The company is headquartered in Södertälje and Nanologica’s share (NICA) is listed for trading on Nasdaq Stockholm Main Market.